SSGJ-707 临床效果获国际认可，财务回报助力公司研发体系升级。SSGJ-707 是三生制药基于CLF2 专 利平台开发的靶向PD-1/VEGF 双特异性抗体，可同时抑制PD-1 和VEGF 双靶点。产品潜力大：1）II 期 临床阶段性分析数据显示，SSGJ-707 在NSCLC 患者的治疗上获得了优异的ORR 和DCR，无论单药还 是与化疗联用，均展示出显著的抗肿瘤活性和良好的安全性，具有best-in-class 的潜力。2）今年4 月获 CDE 突破性治疗药物认定，适应症为一线治疗PD-L1 表达阳性的局部晚期或转移性非小细胞肺癌。此 前，SSGJ-707 已获得FDA 的IND 批准。3）SSGJ-707 用于治疗结直肠癌、妇科肿瘤等领域的临床研究 也在推进中。此次合作证明SSGJ-707优异的临床效果已获得国际顶尖认可，同时验证了公司自主创新 研发体系的国际竞争力，显著提升了公司在肿瘤治疗领域的全球话语权，有力地推进了公司的国际化步 伐。此外，此次合作也将为三生制药带来强劲的财务回报，助力公司研发体系升级，推动公司更好地融 入全球生物医药产业价值链。 机构：国盛证券 研究员：张金洋/胡偌碧/张玉 ...

特比澳、蔓迪等核心产品高速增长，有望支撑公司未来主业稳健增长。特比澳24 年销售50.6 亿元，同 比保持20.4%高增长，市占率34.3%，且24 年医保谈判成功零降价续约并新增儿童ITP 适应症，未来有 望持续增长。促红素双品牌24 年销售10.2亿元，同比+8.3%，市占率42%稳居第一。蔓迪生发24 年销售 13.4 亿元，同比+18.9%，尤其24H2 蔓迪销售恢复高增长，后续通过不断开发新系列品种，品牌销售有 望持续增长。此外，公司不断与众多药企达成创新合作，例如HER3/EGFR 双抗ADC、HER2 ADC、克 立福替尼、口服紫杉醇、GLP1 等，有望提供业绩增量。 盈利预测与评级：考虑12.5 亿美金首付款于25 年确认，预计公司归母净利润分别为97.88/29.88/34.72 亿 元，同比增速分别为368.2%/-69.5%/16.2%，当前股价对应PE 分别为4/14/12 倍。25 年公司经调整净利 润有望达23 亿元，参考瀚森制药、石药集团、康哲药业、中国生物制药等可比公司，给予10 倍PE，主 业合理估值约230 亿元。本次BD 交易金额超预期，我们上调707 双抗海外峰值至50 ...

Core Viewpoint - The company reported significant growth in revenue and a reduction in net loss for Q1 2025, indicating a positive trend in financial performance and operational efficiency [1][2]. Financial Performance - In Q1 2025, the company achieved revenue of 10.02 billion, a year-on-year increase of 187.1% [1]. - The net profit attributable to shareholders was -130 million, a substantial improvement from -1.01 billion in the same period of 2024 [1]. - The gross margin reached a historical high of 14.9% in Q1 2025, compared to -1.4% in Q1 2024 and 13.3% in Q4 2024, reflecting a 1.6 percentage point increase quarter-on-quarter [1]. Sales and Delivery - The company reported a significant increase in vehicle deliveries, with a total of 87,552 units delivered in Q1, representing a year-on-year growth of 162.1% [2]. - The C series models accounted for 67,812 units delivered, making up 77.5% of total sales, which is an increase of 5.7 percentage points compared to the same period in 2024 [2]. - The newly launched B platform model, B10, has seen over 10,000 units delivered since its launch on April 10, 2025, indicating strong market demand [2]. Future Outlook - The company is projected to achieve net profits of 407 million, 1.457 billion, and 3.131 billion for the years 2025 to 2027, with corresponding price-to-earnings ratios of 188.20, 52.52, and 24.44 [2].

Core Viewpoint - The company reported strong Q1 performance with revenue of 10.02 billion yuan, a year-on-year increase of 187.1%, despite a quarter-on-quarter decline of 25.6%, and a net loss of 130 million yuan, which exceeded expectations of a loss between 500 million to 1 billion yuan [1] Group 1: Q1 Performance Highlights - Q1 revenue reached 10.02 billion yuan, driven by a significant year-on-year increase of 187.1% and a quarter-on-quarter decrease of 25.6% [1] - The company delivered 87,552 vehicles in Q1, representing a year-on-year increase of 162.1%, which strongly contributed to revenue growth [1] - The gross margin for Q1 was 14.9%, marking a historical high, with improvements attributed to scale effects from increased sales, ongoing cost management, and an optimized product mix [1] Group 2: Future Outlook and Strategic Initiatives - The company is entering a strong new vehicle cycle in 2025, with three models from the B platform set to launch and updates for D and C platform models expected [2] - The company has expanded its distribution network, with 756 stores covering 279 cities as of Q1 2025, and plans to add 80 more cities by the end of the year [2] - International expansion is accelerating, with 7,546 units exported in Q1 and over 500 overseas outlets established, alongside plans for local assembly in Malaysia and localized manufacturing in Europe by 2026 [2] Group 3: Financial Projections and Valuation - Revenue projections for 2025-2027 are set at 68.7 billion yuan, 91.4 billion yuan, and 116.7 billion yuan, respectively, with net profits expected to be 350 million yuan, 2.04 billion yuan, and 4.31 billion yuan [2] - The company is assigned a target price of 81.15 HKD for 2025, reflecting a 10% premium due to the anticipated strong new vehicle cycle, rapid localization, and strategic partnerships [2]

Core Viewpoint - Leap Motor reported impressive performance in Q1 2025, driven by new vehicle launches and accelerated overseas market expansion, maintaining a "Buy" rating [1] Financial Performance - In Q1 2025, Leap Motor achieved revenue of 10.02 billion yuan, a year-on-year increase of 187% but a quarter-on-quarter decrease of 26% [1] - The net loss for Q1 2025 was 130 million yuan, significantly narrowed compared to previous periods [1] - The gross margin reached 14.9%, an increase of 16.3 percentage points year-on-year and 1.6 percentage points quarter-on-quarter, marking a historical high [1] Sales and Delivery - Leap Motor delivered 88,000 new vehicles in Q1 2025, a year-on-year increase of 162% but a quarter-on-quarter decrease of 28% [2] - The C series accounted for 68,000 units, representing approximately 76% of total sales, with a year-on-year increase in sales proportion by 5.7 percentage points [2] - The average revenue per vehicle was 114,000 yuan, up by 1,000 yuan year-on-year and 300 yuan quarter-on-quarter [2] Export and Global Expansion - In the first four months of 2025, Leap Motor became the top new energy vehicle exporter, with 13,632 units exported, including 7,546 units in Q1 2025 [2] - The company has established over 500 sales and after-sales service points overseas [2] - By the end of 2025, Leap Motor plans to start assembling the right-hand drive version of the C10 model in Gurun, Kedah, Malaysia, aiming for deeper penetration in the Southeast Asian market [2] - The company aims to achieve localized manufacturing in Europe by 2026 to accelerate market expansion [2]

新城发展考虑在境内发行担保债券，计划筹资15至20亿元人民币。（彭博） ...

Group 1 - The Hang Seng Index opened down 0.33% and the Tech Index opened down 0.11% [1] - Xpeng Motors (09868.HK) opened up 9.74% after reporting better-than-expected earnings and guidance [1] - Weibo opened up 2.71% with a Q1 net profit attributable to shareholders increasing by 116.36% year-on-year [1]

近期，阳光保险集团（股票代码：06963.HK）发布公告称，其附属公司阳光资产拟发起设立全资基金 管理公司，并筹备成立"阳光和远私募证券投资基金"（暂用名），总规模达200亿元，由阳光人寿全额 认购。据悉，该基金投资范围覆盖沪深300指数成分股、恒生港股通指数成分股及相关指数ETF。 事实上，这正是近年来险资积极入市的一个缩影，其背后不止是行业响应政策号召的集体选择，也是险 资通过权益市场为实体经济和保险公司自身带来深层价值的战略路径。 一、险资入市成趋势，政策驱动与行业共振 据了解，阳光保险此次布局私募证券基金其实由来已久，早在去年中国人寿和新华保险试点成立保险私 募证券投资基金之际，阳光保险就已开始紧密跟踪，结合公司情况深入研究。 去年9月，保险业新"国十条"发布，随后国家金融监督总局在国务院新闻发布会上表示扩大保险资金长 期投资改革试点，支持其他符合条件的保险机构设立私募证券投资基金，进一步加大对资本市场的投资 力度。为响应发挥保险资金长期投资优势，支持资本市场持续稳健发展，阳光保险第一时间作出基金设 立的申请。 其实除了阳光保险外，还有多家险企也参与到长期投资布局中。据公开资料，截至目前已有三批保险资 ...

Group 1: China Resources Beer - China Resources Beer has seen a recovery in beer sales in April, rebounding from a slowdown in March, with Heineken being a key driver, achieving a 20% growth [1] - The company plans to reduce sales scale in the face of challenges in the liquor industry and aims to control operational expenses through regulated channel investments [1] - China Resources Beer maintains its 2025 targets of low single-digit growth in sales and average price, with expectations of double-digit profit growth [1] Group 2: Hong Kong Liquor Tax Policy - The reduction of high-end liquor tax in Hong Kong has led to a significant increase in imported liquor, with quantities rising over 15% and values increasing nearly 60% compared to the previous period [2] - This tax adjustment is beneficial for liquor companies, especially high-end liquor brands, allowing them to expand sales through Hong Kong as an export hub [2] - The price reduction of Moutai in the Hong Kong market has narrowed the gap with international liquors, attracting more international buyers and consumers [2] Group 3: Fenjiu's Satellite Launch - The successful launch of the "Fenjiu Starship" satellite enhances Fenjiu's brand recognition and international influence, marking a significant honor for the company [3] - This initiative represents a systematic upgrade of Fenjiu's brand value, breaking traditional marketing limitations and enhancing its international market presence [3] - The collaboration with the aerospace sector allows Fenjiu to innovate its marketing and cooperation models, supporting its high-end and international strategic layout [3] Group 4: Yingjia Gongjiu's Stock Response - Yingjia Gongjiu has acknowledged recent stock price declines and emphasized its focus on core business, product optimization, brand enhancement, and deepening marketing efforts [4] - The company's performance growth in Q1 2025 was significantly below the industry average, with stock prices hitting a three-year low [4] - The response to investor concerns appears to be a defensive public relations strategy, lacking any mention of buyback or increase plans, which may not boost investor confidence [4]

智通财经APP获悉，近期，港股医药板块持续爆发，香港医药ETF盘中一度大涨超2%，三生制药、百济 神州、信达生物等集体走强，医药赛道成为资金关注焦点。受益于板块强势反弹，国内最大的院外医药 销售平台——药师帮（09885）股价呈现走强趋势。截至21日收盘，药师帮年内累计最大涨幅超68%， 总市值回升至56亿港元以上。 今年以来，药师帮持续释放积极信号。2024业绩报告显示，公司首次实现全年盈利转正，经调净利润 1.57亿元，同比增20.1%。高毛利业务增长提速，今年1-4月厂牌首推业务成交规模达7.17亿元，同比增 长108.1%；自有品牌业务规模达5.6亿元，同比增长532.3%，逐步形成新的增长势能。现金流表现强 劲，其经营性现金流在过去三年迅猛增长：2022年净流入9820万元，2023年猛增至4.51亿元，并在2024 年继续增长至6.56亿元。 基于对自身业绩和未来市场的正面预期，药师帮于5月7日宣布启动亿元规模的股份回购计划，并于5月7 日—21日累计回购共445.7万股股份，总回购金额超3399万港元。其中，公司于5月21日回购75万股，单 日回购金额超624.6万元。 据香港联交所股权披露信息 ...